Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132169 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
A Phase 3 study, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
NCT02132169: Completed Phase 3 study, sponsored by Aciex Therapeutics.
NCT02132169 is a Phase 3 study that has completed, run by Aciex Therapeutics. The registered enrollment target is 512 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02132169, a Phase 3 study, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
Primary Outcome
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
Interventions
- DRUG AC-170 0%
- DRUG Drug: AC-170 0.24%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
What the finished NCT02132169 record still lists
NCT02132169 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which AC-170 0% is the first listed.
NCT02132169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02132169 about?
NCT02132169 is a clinical study titled "A Multi-Center Study Evaluating the Safety of AC-170 0.24%". The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
What is the current status of trial NCT02132169?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2014-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02132169?
The interventions under investigation include: AC-170 0% (DRUG), Drug: AC-170 0.24% (DRUG).
Who is sponsoring clinical trial NCT02132169?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02132169's enrollment target sits among peer trials
512 728th of 2000 higher than 1,273 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia